$0.91
(Market cap
$35,161 Mln
Revenue (TTM)
$2,536 Mln
P/E Ratio
32.7
P/B Ratio
4
Div. Yield
1.5 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
5.1 %
-
Industry P/E
--
-
EV/EBITDA
20.3
-
Debt to Equity
1.3
-
Book Value
$--
-
EPS
$1.5
-
Face value
--
-
Shares outstanding
445,277,344
10 Years Aggregate
CFO
$13,861.45 Mln
EBITDA
$11,032.20 Mln
Net Profit
$7,008.91 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Royalty Pharma Plc (RPRX)
| 61.3 | 6.7 | 11.8 | 73.2 | 27.9 | 10.0 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Midcap 400
| 11.2 | -1.0 | -0.1 | 14.3 | 12.0 | 6.2 | 9.0 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Royalty Pharma Plc (RPRX)
| 51.5 | -28.9 | -0.8 | -20.4 |
|
S&P Midcap 400
| 5.9 | 14.4 | -14.5 | 23.2 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Royalty Pharma Plc (RPRX)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20... development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York. Read more
-
Founder, Chairman of the Board & CEO
Mr. Pablo Gerardo Legorreta
-
Founder, Chairman of the Board & CEO
Mr. Pablo Gerardo Legorreta
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Royalty Pharma Plc (RPRX)
What is the current share price of Royalty Pharma Plc (RPRX) Today?
The share price of Royalty Pharma Plc (RPRX) is $62.32 (NASDAQ) as of 01-Sep-2026 16:06 EDT. Royalty Pharma Plc (RPRX) has given a return of 27.85% in the last 3 years.
What is the current PB & PE ratio of Royalty Pharma Plc (RPRX)?
The P/E ratio of Royalty Pharma Plc (RPRX) is 32.72 times as on 28-Aug-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
28.05 |
3.34 |
2024 |
17.49 |
2.16 |
2023 |
14.90 |
2.59 |
2022 |
482.20 |
3.67 |
2021 |
39.04 |
2.36 |
What is the 52 Week High and Low of Royalty Pharma Plc (RPRX)?
The 52-week high and low of Royalty Pharma Plc (RPRX) are Rs 62.58 and Rs 34.08 as of 02-Sep-2026.
What is the market cap of Royalty Pharma Plc (RPRX)?
Royalty Pharma Plc (RPRX) has a market capitalisation of $ 35,161 Mln as on 28-Aug-2026. As per SEBI classification, it is a Mid Cap company.
Should I invest in Royalty Pharma Plc (RPRX)?
Before investing in Royalty Pharma Plc (RPRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.